Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-09
2007-10-09
Henley, III, Raymond J. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C424S602000, C424S678000, C424S682000
Reexamination Certificate
active
10467459
ABSTRACT:
A combination therapy for the treatment of heart failure, particularly acute heart failure, comprises administering a combination of levosimendan or a pharmaceutically acceptable salt thereof and a calcium ion source and/or an intracellular calcium increasing agent to a patient. The combination shows a synergistic effect even at doses having no effect if administered alone.
REFERENCES:
patent: 4529602 (1985-07-01), Wada et al.
patent: 4745130 (1988-05-01), Wurtman
patent: 4971982 (1990-11-01), Attwood et al.
patent: 5120738 (1992-06-01), Ikawa et al.
patent: 5424428 (1995-06-01), Nore et al.
patent: 5512571 (1996-04-01), Nore et al.
patent: 5569657 (1996-10-01), Nore et al.
patent: 5998458 (1999-12-01), Bristow
patent: 6030943 (2000-02-01), Crumb et al.
patent: 6323226 (2001-11-01), Delgado et al.
patent: 6355269 (2002-03-01), Backman et al.
patent: 6448248 (2002-09-01), Amberg et al.
patent: 6531458 (2003-03-01), Larma et al.
patent: 6730673 (2004-05-01), Backstrom et al.
patent: 0 411 766 (1991-02-01), None
patent: 0 565 546 (1995-03-01), None
patent: WO92/12135 (1992-07-01), None
patent: WO93/21921 (1993-11-01), None
patent: WO98/27070 (1998-06-01), None
patent: WO99/16443 (1999-04-01), None
patent: WO99/55337 (1999-11-01), None
patent: WO99/66912 (1999-12-01), None
Handbook of Pharmaceutical Excipients, published 1986 by American Pharmaceutical Association (DC), pp. 26-33.
Cecil Textbook of Medicine, Goldman et al. (editors), 21stEdition, vol. 1, published 2000, pp. 215-225.
Handbook of Pharmaceutical Excipients, published by the American Pharmaceutical Association, 1986, pp. 36-40 and 44.
F. Guideri et al., “Calcium infusion induces myocardial ischaemia in patients with coronary artery disease by a mechanism possibly adenosine mediated”, European Heart Journal, vol. 15, pp. 1158-1163 (1984).
Nicolai Gruhn et al., “Coronary Vasorelaxant Effect of Levosimendan, a New Inodilator with Calcium-Sensitizing Properties”, Journal of Cardiovascular Pharmacology, vol. 31, pp. 741-749 (1998).
Heimo Haikala et al., “The role of cAMP- and cGMP-dependent protein kinases in the cardiac actions of the new calcium sensitizer, levosimendan”, Cardiovascular Research, vol. 34, pp. 536-546 (1997).
Herwig Köppel et al., “Minimal Effects of Levosimendan on Coronary Artery Smooth Muscle Tone”, Cardiovascular Drugs and Therapy vol. 13, pp. 357-358 (1999).
Derwent Abstract of WO 98/27070 (2003).
J. Lilleberg et al., “Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting,” European Heart Journal (1998) 19: 660-668.
Stig Sundberg et al., “Hemodynamic and Neurohumoral Effects of Levosimendan, a New Calcium Sensitizer, at Rest and During Exercise in Healthy Men,” Am. J. Cardiol (1995) 75:1061-1066.
Esa-Pekka Sandell et al., “Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart Failure,” Journal of Cardiovascular Pharmacology, 26 (Suppl. 1): S57-S62 (1995).
J. Lilleberg et al., “Dose-Range Study of a New Calcium Sensitizer, Levosimendan, in Patients with left Ventricular Dysfunction”, Journal of Cardiovascular Pharmacology, 26 (Suppl. 1): S63-S69 (1995).
Lynette R. Moser et al., “The use of calcium salts in the prevention and management of verapamil-induced hypotension”, American Chemical Society (2002)—Abstract 133:159.
William G. Hughes et al., “Should Calcium Be Used in Cardiac Arrest?,” The American Journal of Medicine, (1986) 81:285-296.
Finnegan Henderson Farabow Garrett & Dunner LLP
Henley III Raymond J.
Orion Corporation
LandOfFree
Method for the treatment of heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the treatment of heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the treatment of heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3852694